During the first BASIC meeting, Council members received updates on several ongoing pilot activities including the Observational Medical Outcomes Partnership (OMOP), Mini-Sentinel, the Exploring and Understanding Adverse Drug Reactions (EU-ADR) Project, and the Vaccine Safety Datalink.
Recognizing similarities among these pilot activities, the Council considered potential opportunities for sharing findings and minimizing overlap. Following a presentation by McKinsey & Company on lessons learned from public-private partnerships and complex alliances in other industries, the Council discussed governance of the Sentinel System. Specifically, Council members explored the merits of potential organizational models focusing on governance for multiple users and multiple uses, economic sustainability, and ensuring participation of appropriate stakeholders.
Agenda
-
June 2
-
Welcome, Introduction, Charge to the Council, and Meeting Objectives
-
Remarks from FDA Leadership
-
Session I: U.S.-Based Medical Product Active Surveillance Pilot Projects
Richard Platt Professor and Chair, Department of Population Medicine - Harvard Pilgrim Health Care Institute -
Council Discussion
Myrl Weinberg Chief Executive Officer - National Health Council -
Session II: Other Initiatives That Can Inform Development of the Sentinel System
-
Session III: Organization Models for the Sentinel System
-
Discussion Summary and Next Steps
-